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REVIEW
Abstract: By virtue of their efficacy, opioid analgesics have long been used for the treatment
of both acute and chronic pain. Concerns regarding their safety and tolerability have frequently
prevented this class of drugs achieving their full therapeutic potential, and their reported
association with drug abuse and dependence has led to a reduced acceptance by many patients.
Indeed, there is a variety of opioid-like side effects which are common to all members of the
class, but some opioids have a more favourable safety profile than others. Buprenorphine is a
semisynthestic opioid with a µ-agonistic and κ-antagonistic receptor-binding profile. Studies
over the past two decades have shown buprenorphine to have a complex and unique
pharmacological profile, which results in enhanced therapeutic benefits combined with a
favourable safety profile. Having been underused before, the development of a new transdermal
drug delivery system for buprenorphine has revived interest in this substance. Transdermal
buprenorphine (Gruenenthal GmbH, Aachen, Germany) provides a noninvasive method of
rate-controlled drug release ensuring constant and predictable serum buprenorphine levels
over a prolonged period. This preparation has been shown to be advantageous for long-term
treatment of chronic pain patients providing reliable pain control, few adverse events, and
good patient acceptance.
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Introduction
Opioid analgesics play an important role in the management of acute and chronic
pain of both cancer and non-cancer origin, particularly where non-opioid analgesics
have proven to be not effective. The World Health Organisation (WHO) guidelines
for cancer pain management propose the use of an analgesic pain ladder, suggesting
the use of mild opioids such as codeine for mild to moderate pain (step II) progressing
to the use of strong opioids such as morphine to control severe pain (step III) (WHO
1996).
Despite their proven efficacy for the control of chronic pain, the use of opioids
have frequently been curtailed due to concerns regarding safety and tolerability. By
its very nature, persistent pain necessitates the use of long-term therapy, which in the
case of opioids leads to mostly unsubstantiated fears concerning drug abuse, addiction,
and dependency. For many patients with chronic pain, however, opioid therapy may
be the only effective treatment. Side effects and safety are of paramount importance
in these cases where quality of life is often compromised. A number of treatment
goals have now been proposed for improved patient therapy, most of which are based
on the WHO recommendations. These include providing a stable plasma drug
concentration to ensure long lasting and effective pain relief, formulations that
provide a long duration of action, noninvasive administration, and an improved
quality of life.
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Buprenorphine, a potent opioid analgesic, has been
available in parenteral and sublingual formulations for more
than two decades. It offers a number of advantages when
compared with morphine and its physicochemical properties
make it a suitable candidate for administration in a
transdermal preparation.
In this paper we will review the safety aspects of long-
term opioid therapy and show why and how transdermal
buprenorphine is especially suitable for chronic pain
management.
Buprenorphine
Physicochemical properties
Buprenorphine is a semi-synthetic derivative of thebaine,
one of the chemically most reactive morphine alkaloids.
Buprenorphine has a molecular weight of 467 and its
structure is typically opioid with the inclusion of a C-7 side-
chain containing a t-butyl group. This group confers overall
lipophilicity on the molecule which has an important
influence on its pharmacology.
Opioids exert their pharmacological effects by binding
to opioid receptors. The pharmacological effects are
determined by the nature of opioid-receptor interaction.
Some of these effects such as analgesia, mediated by an
agonistic action at the µ-opioid receptor are desirable,
whereas others such as nausea, sedation, or constipation can
be considered as unwanted adverse effects. Buprenorphine
is a µ-opioid receptor agonist with high affinity, but low
intrinsic activity. Compared with morphine which behaves
as a full µ-opioid agonist, buprenorphine is usually defined
as a partial µ-opioid agonist that shows high affinity for and
slow dissociation from the µ-opioid receptor. A full dose-
dependent effect on analgesia has been seen within the
clinically relevant dose range (up to 10 mg), but no
respiratory depression which levels off at higher doses
(Dahan et al 2005). Clinically, there is also a less marked
effect of buprenorphine-binding to µ-opioid receptors on
gastrointestinal transit times, and indeed constipation seen
in the clinic is remarkably low (Griessinger et al 2005).
Buprenorphine also shows partial agonistic activity at the
opioid receptor-like receptor 1 (ORL1)-receptors which are
(at least at supraspinal receptors) postulated to induce a
pronociceptive effect. A study by Lutfy et al (2003) reported
that co-activation of ORL1-receptors compromises the
antinociception induced by activation of the µ-opioid
receptor. ORL1-activation has also an effect on hyperalgesia.
It might be that buprenorphine’s partial agonism reduces
this effect compared with full ORL1-agonists such as
morphine or fentanyl. Buprenorphine’s antagonistic action
at the δ-receptors which have a marked anti-opioid action
and seem to negatively modulate central analgesia seems
further to contribute to its clinically seen analgesic effect.
Its likewise antagonistic activity at the κ-opioid receptors
might explain the fact that it induces much less sedation
and psychotomimetic effects than morphine or fentanyl
(Lewis 1985; Leander 1988). Animal studies have shown
that buprenorphine has a 20–40 times higher potency than
morphine (Martin et al 1976).
The strong binding of buprenorphine to the µ-opioid
receptor has several consequences. Initial binding is
relatively slow compared with other opioids such as fentanyl
(Boas and Villiger 1985). However, the onset of analgesia
is not dissimilar, since buprenorphine achieves effective
analgesia at relatively low receptor occupancy (5%–10%)
(Tyers 1980) and thus relatively low plasma concentrations
of buprenorphine are sufficient to provide effective pain
relief. The slow dissociation of buprenorphine from the
receptor results in a long duration of effect and also confers
another advantage in that when the drug is withdrawn an
abstinence syndrome is rarely seen because of the long time
taken for the drug to come off the receptor (Bickel et al
1988).
Pharmacokinetics
Due to the high first-past effect (95%) seen after oral
administration, Buprenorphine was initially available as
either a parenteral or sublingual formulation. Onset of
analgesia after sublingual administration has been shown
to occur within 15 to 45 minutes with peak plasma
concentrations reached after two hours (Bullingham et al
1980). The transfer half-life estimated at 76 minutes is
consistent with a systemic availability completed within
5 hours. Average bioavailability with sublingual dosing was
found to be 55% (McQuay et al 1986). The parenteral
formulation of buprenorphine has a speed of onset within
5–15 minutes of either intravenous (IV) or intramuscular
(IM) administration. As characteristic of lipophilic
compound, buprenorphine exhibits multiphasic clearance;
an initial rapid clearance followed by slower clearances
observed after IV injection (McQuay and Moore 1995).
In the body, buprenorphine is highly protein-bound
mostly to α-globulin and β-globulin fractions (Heel et al
1979). Since most drugs bind to albumin, there is no risk of
competition for binding proteins, resulting in a lower riskTherapeutics and Clinical Risk Management 2006:2(1) 117
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of interactions. Buprenorphine conjugates with glucuronic
acid, which explains the low bioavailability of only 5% in
the case of oral administration. In the liver, buprenorphine
is metabolised to norbuprenorphine (N-dealkylbuprenor-
phine) and buprenorphine glucuronide. While the latter has
no analgesic activity, norbuprenorphine exerts a weak
analgesic action, but is of minor clinical importance (Ohtani
et al 1995). After parenteral administration two thirds of
the dose of buprenorphine is excreted unchanged in the
faeces and one third is metabolised in the liver and
eliminated as conjugates in the urine or bile (Heel et al 1979).
In short-term treatment with buprenorphine, end-stage renal
failure does not affect excretion of the drug.
Side effects
Buprenorphine has the typical side effects shown by all
opioids including nausea, vomiting, dizziness, constipation,
and headache. In a study of patients with chronic nociceptive
pain, the analgesic efficacy of sublingual buprenorphine and
sustained release morphine were similar, but the patients
treated with buprenorphine had significantly fewer side
effects (Bach et al 1991). This was particularly noticeable
with respect to nausea, vomiting, and constipation and may
in part be attributed to the sublingual route of administration
bypassing the gut µ-opioid receptors. As with all other strong
opioids, buprenorphine produces respiratory depression. In
contrast with fentanyl and morphine, a ceiling effect has
been shown to exist for buprenorphine-induced respiratory
depression (Doxey et al 1982; Dahan et al 2005). This is
consistent with the partial agonist profile of buprenorphine
and the relevance of this factor with regard to the safety of
the drug in clinical practice will be discussed later. The
respiratory depressant effect of buprenorphine has been
shown to respond to naloxone, an antagonist at the µ-opioid
receptor, such that the effect can be completely reversed
(Gal 1989; Dahan et al 2005).
Clinical efficacy
Buprenorphine is an effective analgesic with a potency at
least 30 times that of morphine. The smallest dose
recommended for IM use (0.3 mg) has been shown to be as
effective as morphine (10 mg) but has a longer duration of
action (6–18 hours) (Kay 1978). The accepted range for
buprenorphine analgesic effects is 0.1–10 mg and in this
range the drug behaves as an agonist with no flattening of
the dose response curve at less than 100% effect.
Buprenorphine given intravenously in the dose range of
0.4–7.0 mg for postoperative pain was found to be a potent,
long-lasting safe analgesic with a minimum number of side
effects, a dose-related efficacy and thus no ceiling effect
for analgesia (Budd 1981).
The treatment of neuropathic pain represents a challenge
to clinicians and there is controversy regarding the efficacy
of opioids in this condition. The abnormal pain sensitivity
caused by neuropathy including hyperalgesia and allodynia
is often resistant to opioid therapy. Buprenorphine has been
shown to have a pronounced antihyperalgesic effect. In
contrast to pure µ-agonists, buprenorphine-induced
antihyperalgesic effects have a significant longer half life
compared with its analgesic effects (Koppert et al 2005).
These findings might account for the clinical efficacy in
pain states dominated by hyperalgesia and central
sensitization such as postoperative pain or neuropathic pain.
Clinically, it has been shown that IV buprenorphine is
effective in the treatment of post-thoracotomy neuropathic
pain, albeit at a higher dosage than required to treat
nociceptive postoperative pain (Benedetti et al 1998).
Further, buprenorphine is the only opioid where
antinociception is not blocked by pertussis toxin which is
an experimental model to study the pathophysiology of
neuropathic pain (Womer et al 1997; McCormack et al
1999). Sublingual buprenorphine tablets have undergone
extensive evaluation as analgesic agents for acute and
chronic cancer-related pain and have additionally become
a valuable agent with which to treat opioid dependency.
Transdermal delivery systems
Transdermal delivery systems (TDS) have now been used
for more than 10 years in situations other than pain
management and have been shown to provide effective and
well-tolerated drug delivery (Berner and John 1994; Ly et
al 2001). They are not suited for all drugs but have several
advantages over traditional routes of administration,
including noninvasive administration and rate-controlled
drug release. The TDS formulation is designed to overcome
the pharmacokinetic problems of both oral and parenteral
opioids including poor gastrointestinal absorption, first pass
metabolism and low bioavailability. This formulation is
particularly useful for patients with pre-existing gastro-
intestinal problems and may improve patient compliance
and quality of life. The high analgesic potency of
buprenorphine, its high lipophilicity, and low molecular
weight combined with a low abuse potential, make it an
ideal drug for use in a TDS system. Together with anotherTherapeutics and Clinical Risk Management 2006:2(1) 118
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opioid, fentanyl, buprenorphine is the only opioid available
in a transdermal formulation.
The transdermal buprenorphine
patch (Transtec®)
The transdermal buprenorphine patch, Transtec
®, was first
launched in Switzerland and Germany in 2001 and is now
marketed all over Europe. Using matrix technology,
buprenorphine is homogeneously incorporated in a solid
polymer matrix patch which is applied to the skin. The
adhesive buprenorphine patch is noninvasive and slowly and
continuously releases the drug into the systemic circulation.
This matrix patch structure avoids the risk of ‘dose-
dumping’, a feature of older reservoir patch systems, which
use a regulating membrane to restrict drug diffusion (Budd
2003). Transdermal buprenorphine is available in three
different dosage strengths with total loading doses of 20 mg,
30 mg, and 40 mg designed to release buprenorphine at a
steady controlled rate of 35 µg/h, 52.5 µg/h, and 70 µg/h,
respectively. This corresponds to an administered daily
buprenorphine dose of 0.8 mg/day, 1.2 mg/day, and 1.6 mg/
day. The minimum effective concentration (MEC) for cases
of moderate to severe pain is in the region of 100 pg/ml
(Budd 2002). Pharmacokinetic studies have shown that after
single application of the patch plasma levels of
buprenorphine continuously increase and reach the MEC
after 24 hours using the 35 µg/h patch and 12 hours using
the larger 70 µg/h patch. (Sittl et al 2003). The initial
recommendation on dose maintenance was that each patch
remained effective for 72 hours. However, a recent open,
randomised cross-over-study in chronic pain patients found
that clinically effective plasma concentrations are reached
after 24 hours and that these levels are maintained for the
entire 96 hour application period (Likar 2005). The 96 hour
buprenorphine TDS application was found to be bio-
equivalent to the 72 hour application with regard to area
under the curve (AUC) and concentration maximum (Cmax)
This allows twice weekly changing of the patch on fixed
days (eg, always on Mondays and Thursdays), facilitating
therapy for patients, increasing patient compliance, and
rendering pain therapy more cost-effective.
Indications and dosing
Transdermal buprenorphine is indicated for the treatment
of moderate to severe cancer-related pain and severe pain
unresponsive to nonopioid analgesics, including neuropathic
pain. It is not indicated for use in cases of acute pain.
Studies of the use of transdermal buprenorphine in
patients with chronic tumor and non-tumor pain have shown
that the patches achieved a good analgesic effect and reduced
the need for additional oral analgesics. In addition, the
quality of life of the patient was improved in comparison
with conventional therapies, benefits including an increased
duration of sleep (Likar et al 2003; Sittl et al 2003). A survey
of 13 179 chronic pain patients of varying aetiologies
including musculoskeletal, neurogenic, and cancer pain
confirmed effective analgesia was provided by treatment
with transdermal buprenorphine. Most of the patients had
been pretreated with WHO step II or step III opioids,
although 30% had not previously been prescribed any
opioids. Pain relief was rated as good or very good by 81%
of the respondents at the end of the observation period
(Griessinger et al 2005).
In advanced cancer pain and the final stages of the
disease nearly 50% of patients will require parenteral
medicine (Zech et al 1995). In these cases, transdermal
preparations such as transdermal buprenorphine or
transdermal fentanyl offer noninvasive alternatives. A study
of three patients with severe pain due to renal and
metastasing prostate and breast cancer has shown
buprenorphine TDS to be a valuable option, providing
effective long-term treatment without dose escalation or
compromise in tolerability (Schriek 2004). The efficacy and
safety of buprenorphine 70 µg/h has been demonstrated in
a trial in patients with chronic tumor-related pain requiring
morphine 90–150 mg/day (Poulain et al 2005),
demonstrating that transdermal buprenorphine works
effectively in the high-dose range of morphine (ie, on step
III of the WHO ladder) and is therefore a viable alternative
to morphine.
Likar and Sittl (2005) reported that transdermal
buprenorphine is very effective in patients with neuropathic
pain or with pain having a strong neuropathic component
when other opioids failed. The effectiveness of transdermal
buprenorphine in neuropathic pain has also been investigated
by Rodriguez et al (2004) in a study population of 237
patients (37% male, 63% female) who suffered from various
typical neuropathic symptoms or pain syndromes where
neuropathic pain constituted a major component. After
4 weeks treatment with transdermal buprenorphine, a clear
decrease in the percentage of patients reporting moderate
to severe pain and a corresponding increase in the percentage
reporting none or only slight pain was documented.
Although more studies are clearly needed in this area, it
seems clear from already available data that buprenorphineTherapeutics and Clinical Risk Management 2006:2(1) 119
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is one of the most promising opioids for the treatment of
neuropathic pain.
The equipotency ratio of transdermal fentanyl to oral
morphine has been established as 1:100 (Donner et al 1996).
The comparable ratio for transdermal buprenorphine to oral
morphine has been proposed to be 1:75, although clinical
experience including data from postmarketing-surveys
(Griessinger et al 2005; Muriel et al 2004) suggested that
buprenorphine TDS may be more potent than initially
suggested. A retrospective analysis in patients with both
cancer and non-cancer pain has compared calculated
equipotent oral morphine doses of transdermal fentanyl with
equipotent morphine doses of buprenorphine prescribed in
clinical practice and suggested that an equipotency ratio of
1:110 to 1:115, morphine to transdermal buprenorphine,
may be more appropriate (Sittl, Likar, et al 2005).
Switching and combining with other
opioids
The goal of pain management with opioids is to provide
optimal analgesia with a minimum of adverse events. WHO
guidelines on cancer pain recommend a switch of opioid if
the current treatment is no longer of sufficient efficacy or if
intolerable adverse events occur. Switching therapy to and
from buprenorphine to or from other opioids does not present
major problems.
It has been suggested that buprenorphine being a partial
agonist at the same receptor site as morphine might block
the effects of morphine if a patient was switched to
morphine. Clinical studies have shown this not to be the
case and in the analgesic dose range, a switch between
buprenorphine sublingual (SL) and an equianalgesic dose
of oral morphine sulphate was carried out without problems
for the patient (Atkinson et al 1990). More recent animal
studies involving combined use of buprenorphine and other
opioids have indicated that a moderate antagonistic effect
attributed to the partial µ-agonistic properties of bupren-
orphine was only seen when doses exceeded the therapeutic
dose range, otherwise both morphine and fentanyl showed
full efficacy (Koegel et al 2005).
Although morphine is considered to be the gold standard
drug in pain management according to step III of the WHO
analgesic ladder and may provide adequate analgesia for
many patients, there are some who suffer from intolerable
side effects and/or inadequate pain relief with morphine.
Therefore a change also of formulation could be beneficial.
As a subanalysis of a large postmarketing survey on
buprenorphine TDS found, patients who had been switched
from high daily doses of morphine (> 120 mg) to at least
52.5 µg/h transdermal buprenorphine, benefited from an
average 50% reduction in pain after the switch (Gruenenthal,
data on file, publication in preparation). In 70% of the
patients this was achieved without the additional use of other
opioid medication.
Concerns with long-term therapy
Tolerance development
Long-term use of opioids may lead to the development of
tolerance requiring higher doses to be administered in order
to produce a given level of response. Tolerance to analgesia
may not be accompanied by tolerance to opioid-induced
adverse effects so that dose escalation can often result in a
negative impact on the adverse events profile.
The development of tolerance to opioids may be brought
about by desensitization and down-regulation in µ-opioid
receptors in response to agonist treatment. Both fentanyl
and morphine have been shown to induce a loss of surface
receptors, while buprenorphine was found to cause an
increase (Zaki et al 2000). Although tolerance to bupren-
orphine may develop to many of its other effects as indicated
in animal models, tolerance to its analgesic effects in chronic
pain patients has not been shown (Robinson 2002).
A study of long-term management of chronic cancer and
non-cancer pain showed that the proportion of patients
needing 1 mg of sublingual buprenorphine daily in addition
to the 35 µg/h patch remained essentially stable throughout
the first 6 months of the study, which points to the dose
stability of buprenorphine. In addition, 31% of patients were
able to control their pain by using only one of the lowest
dose patches throughout (Likar et al 2005). When treatment
with transdermal fentanyl and buprenorphine TDS for at
least 3 months was compared in a retrospective study study
on cancer and non-cancer patients, a significantly higher
increase in mean daily doses of fentanyl compared with
buprenorphine was found (Sittl, Nuitjen, et al 2005).
Safety
Respiratory depression
Respiratory depression caused by opioids can be potentially
life-threatening, but is much less of a problem with
buprenorphine than with many other opioids including
morphine, hydromorphone, methadone, oxycodone, and
transdermal fentanyl (Dertwinkel et al 1998).
Buprenorphine has a ceiling effect associated with a bell-
shaped dose response curve with regard to respiratoryTherapeutics and Clinical Risk Management 2006:2(1) 120
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depression, meaning that the risk to induce respiratory arrest
does not linearly follow dose-increments of the substance.
This ceiling effect provides a safety benefit in case of drug
abuse (Doxey et al 1982). A comparison of the respiratory
effect of intravenous buprenorphine and fentanyl in both
animals and man confirmed a ceiling effect of bupren-
orphine, but not for fentanyl. In healthy human volunteers,
fentanyl produced a dose-dependent depression of
respiration with apnoea at doses ≥ 2.9 µg/kg while
respiratory depression caused by buprenorphine levelled off
at doses ≥ 3.0 µg/kg (Dahan et al 2005). A dose-response
study in healthy male adult volunteers, showed that respiration
was maximally depressed at doses of 16 mg of sublingual
buprenorphine with a slightly reduced effect at 32 mg.
Although 32 mg represents 70 times the recommended
analgesic dose, this dose was well tolerated and produced
no serious adverse effects (Walsh et al 1994). It is therefore
more than unlikely that respiratory depression is caused by
buprenorphine in the analgesic dose range. At very high
doses (above 32 mg) it could occur. As with other opioids,
it can be reversed by the µ-opioid antagonist naloxone, but
due to buprenorphine’s very tight binding to opioid receptors
and its long-lasting effect, higher and repeated doses of
naloxone would be necessary in these rare cases (Dahan et
al 2005). Close monitoring of patients’ respiration is
recommended, especially in anesthesized or sleeping
patients with repeated administration of very high doses of
buprenorphine, but this should also be the case with any
other µ-opioid agonist.
Renal impairment
Patients with renal insufficiency frequently require the use
of opioids for painful syndromes not responsive to other
therapies. This can be a problem particularly in the elderly
where age-related changes can affect glomerular filtration,
tubular secretion, and reabsorption of metabolites. Changes
in renal function may affect the pharmacokinetics of opioids
and necessitate a change in dosage (Mercadante and Arcuri
2004). Whilst morphine itself is largely unaffected by renal
failure, accumulation of its active metabolite morphine-6-
glucuronide cautions its use. Case reports of prolonged
narcosis with both codeine and dihydrocodeine in renal
insufficiency also call for care when using these agents
(Davies et al 1996). The pharmacokinetics of buprenorphine
are not altered in patients with renal failure (Summerfield
et al 1985; McQuay et al 1986; Moore et al 1994). The main
site for metabolism of buprenorphine is the liver, indicating
that impaired renal function should have little influence on
plasma levels. The major metabolite of buprenorphine is
norbuprenorphine. It has been found that levels of this
metabolite may be raised after continuous intravenous
dosing in patients with renal impairment. However, due to
the lower potency and lower affinity of the metabolite for
the receptor compared with the parent drug, it is unlikely
that this is of any consequence (Hand et al 1990). A recent
study of end-stage renal disease patients treated with
buprenorphine TDS showed no elevated levels of
buprenorphine or norbuprenorphine, indicating that a
dose-adaptation in patients with end-stage renal disease
is not necessary and analgesic effects of transdermal
buprenorphine remain stable during treatment (Filitz et
al 2005).
Hepatic impairment
The liver is the major site of biotransformation for most
opioids, which raises the possibility that hepatic
insufficiency may lead to reduced drug metabolism and the
accumulation in the body. If metabolism is decreased the
analgesic effect of the drug may be compromised. The major
metabolic pathway for opioids is oxidation, exceptions being
morphine and buprenorphine, which undergo glucuronida-
tion. It has been shown that although oxidation of opioids
is reduced in patients with hepatic cirrhosis resulting in
reduced drug clearance, glucuronidation is less affected by
liver disease (Tegeder et al 1999). The N-dealkylation of
buprenorphine to norbuprenorphine is catalyzed by the
cytochrome (CYP) P450 enzyme system, with CYP3A4
being the major isoenzyme. Since CYP3A4 protein
expression is reduced in patients with severe chronic liver
disease, patients with this condition should be closely
monitored during treatment (Tegeder et al 1999).
Immunosuppression
Suppression of the immune system frequently occurs as a
result of the trauma of surgery or from medical conditions
such as HIV or cancer. In addition the elderly may be at
particular risk due to the progressive declining function of
the immune system as a consequence of ageing. Most strong
opioids have been found to suppress the immune system to
some extent within the antinociceptive range and careful
selection of therapeutic agent is important particularly in
patients who are already immunocompromised, including
cancer patients at risk of metastatic dissemination. The acute
administration of morphine has been shown in both animals
and humans to significantly reduce cellular immunity and
animals treated with morphine have shown an increase inTherapeutics and Clinical Risk Management 2006:2(1) 121
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experimental infection and cancer. It is considered that
opioid-induced immunosuppression is less relevant in
chronic administration than in acute or short-time
administration.
The immunosuppressive effect of opioids has been linked
to µ-receptor agonism: opioids with high affinity for the
µ-opioid receptor induce significant immunosuppression
while those with κ-receptor of δ-receptor selectivity do not.
Antagonists at the µ-opioid receptor tend to enhance the
immune system (Budd 2004). The immunosuppressive
effects of opioids are independent of their analgesic effects
and appear to be a function of molecular structure. The
opioids with lack of immunomodulatory capacity are
buprenorphine, hydromorphone, oxycodone, oxymorphone,
and tramadol all of which have a carbonyl substitution at
C6 and a single bond between C7 and C8. An assessment of
buprenorphine toxicity in rats indicated that buprenorphine
may have a slight stimulatory effect on the immune system
although the exact mechanism remains unclear (Van Loveren
et al 1994). After 24 hours of administration of fentanyl in
mice, key parameters for immune response were reduced
including natural killer cell activity, lymphoproliferation,
and interleukin-2 and interferon-γ production. By contrast,
neither acute nor chronic administration of equianalgesic
doses of buprenorphine produced any effect (Martucci et al
2004).
Special patient populations
Buprenorphine has been used in children in the past mainly
in acute pain conditions such as postoperative pain where it
proved to be safe and effective irrespective of the
administration route (Maunuksela et al 1988a, 1988b; Kamal
and Khan 1995; Olkkola et al 1995). Basically, the
transdermal formulation is an ideal analgesic device for
children as it is completely noninvasive and produces
longlasting reliable analgesia. In addition, due to their
matrix structure, patches can be cut into halves or quarters
to allow for an easy adaptation to smaller dosing needs of
younger patients. However, as there are as yet no data
available in this patient group, transdermal buprenorphine
is not licensed for children and young patients under the
age of 18, and therefore cannot be recommended to be used
in this group.
For the elderly, ie, patients above the age of 65 years,
transdermal buprenorphine is an easy-to-use, safe, and
effective analgesic device what has also been shown in the
clinic (Griessinger et al 2005; Likar et al 2006, pers comm).
In particular, buprenorphine’s low potential for drug–drug-
interactions (see chapter on Interactions), its beneficial
effects on the immune system, and in patients with renal
impairment, make it the opioid of choice for pain treatment
in elderly patients.
Tolerability
Gastrointestinal adverse events associated with strong opioid
use include nausea, vomiting, and constipation. None of
these conditions present a severe medical risk and can
normally be dealt with by the clinician. Buprenorphine has
a low incidence of adverse events in practice. Following
parenteral use, the incidence of nausea is 8.8% and the
incidence of vomiting is 7.4% (Harcus et al 1979).
Continuous sublingual use in chronic pain has found that
the incidence for nausea falls to 6.5% and for vomiting to
3.5% (Bach et al 1991).
Constipation is another commonly encountered side
effect of opioid use that can significantly affect quality of
life, particularly for elderly patients. The incidence of
constipation with buprenorphine has been shown to be lower
than with morphine use (Bach et al 1991). In a study of
sublingual administration of buprenorphine in 51 elderly
patients with chronic pain, only one patient reported
constipation (Nasar et al 1986). Bypassing the gut µ-opioid
receptors through the use of parenteral or transdermal
preparations of opioids may offer advantages in this respect.
Central nervous system (CNS)-related adverse events
including dizziness, drowsiness, and euphoria may occur at
the start of opioid treatment or following an increase in
dosage. The incidence is directly linked to kidney function.
Any opioid that is mainly excreted by the renal route will
accumulate in patients with renal impairment and has the
potential to cause an increase in the incidence of adverse
events. This situation is particularly relevant in the elderly,
a group in whom renal function may decline often even
unrecognised with increasing age. As only approximately
15% of buprenorphine is excreted by the kidneys the
likelihood of accumulation is low in comparison with either
morphine or fentanyl, where 75% or more is excreted by
the renal route. Buprenorphine has a lower risk of CNS-
related adverse effects than other opioids.
Interactions
A drug–drug interaction occurs when the effect of a
particular drug is modified by another drug taken
concomitantly. This is a situation that may be of particular
concern in the elderly where reduced renal function and
multiple drug therapy are often combined. Competition forTherapeutics and Clinical Risk Management 2006:2(1) 122
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binding sites on plasma proteins such as albumin and α- or
γ-globulins may cause reduced binding and hence increased
levels of unbound drug, which may cause an increased
pharmacological effect. The pharmacological profile of
buprenorphine is favourable in this respect since 96% is
bound to α- or γ-globulins whereas most other drugs bind
to albumin.
Many drugs are metabolised in the liver by the
cytochrome P450 system and those that act as either inducers
or inhibitors of this enzyme system may cause clinically
important drug interactions. Buprenorphine has been
demonstrated to inhibit CYP3A4- and CYP2D6-mediated
reactions, however, at therapeutic concentrations it is
unlikely that either buprenorphine or its metabolite
norbuprenorphine would cause significant interactions with
other CYP-metabolised drugs (Umehara et al 2002; Zhang
et al 2003).
However, all opioids interact with other CNS-depressant
drugs, eg, benzodiazepines, and this might result in an
increased risk of centrally-mediated side effects such as
sedation or respiratory depression. This effect is most likely
due to a synergistic pharmacodynamic effect on the CNS
and not to hepatic metabolism (Ibrahim 2000). There is a
respective class label warning in the summary of product
characteristics (SmPCs) of transdermal buprenorphine and
of all other strong opioids.
Dependence, addiction, and abuse potential
Fear of dependence and addiction is one of the main reasons
why many clinicians have in the past been reluctant to
prescribe opioids. As a drug class, therapeutic doses of
opioids are safe and non-toxic even under chronic dosing
conditions. Supratherapeutic doses of µ-opioid agonists can
be lethal, especially when administered to non-tolerant
individuals. This toxicity is mainly due to the respiratory
depressant action. As previously discussed, in contrast to
many other opioids buprenorphine shows a ceiling effect
with respect to respiratory depression that contributes to its
safety profile. Reports of episodic cases of buprenorphine
abuse have largely been confined to experienced drug
abusers. The abuse potential of buprenorphine, although low,
is further reduced in a transdermal preparation because the
plasma levels slowly rise to a therapeutic level, unlike the
rapid peak level that occurs with other formulations.
There is little evidence that buprenorphine has the
potential to cause dependence and addiction. Even after
prolonged treatment with buprenorphine withdrawal
symptoms after spontaneous withdrawal are relatively
moderate compared with those that occur after comparable
treatment schedules with opioids such as morphine, fentanyl,
or methadone (Tzschentke 2002; Walsh and Eissenberg
2003). This property is probably related to the receptor
kinetics of the drug, as dissociation occurs very slowly once
bound to the µ-opioid receptor. The long duration of action
of buprenorphine (and hence need for less frequent dosing)
has suggested its use in the treatment of opioid addiction.
Buprenorphine has been shown to be capable of blocking
the effects of 120 mg doses of morphine, a blockage that
persisted for 29.5 hours (Jasinski et al 1978). Buprenorphine
in sublingual form has been found to be acceptable to
addicts, and its limited withdrawal effects makes a gradual
reduction in the dose of buprenorphine taken more likely.
The advantages of transdermal
buprenorphine for long-term
therapy
The treatment of chronic pain frequently requires long-term
therapy that may continue for many months or even years.
Transdermal buprenorphine offers an easy to use formulation
which can maintain therapeutic serum levels for up to 96
hours. The availability of sublingual buprenorphine tablets
for use as supplementary medication in breakthrough pain
episodes is in line with the WHO recommendation for an
immediate release formulation containing the same
substance for rapid pain relief if required.
In terms of handling, transdermal buprenorphine offers
a number of advantages. The patch can be applied by the
patient or carer, it is unobtrusive and sticks on well over the
full dosage period. In a study of 239 chronic pain patients
who used buprenorphine TDS for a mean period of 7.5
months, 93.3% rated handling of the patch as “without
problem” (Likar et al 2005). Buprenorphine TDS can be
used by patients with swallowing difficulties and results in
less tablet intake, an important feature for the elderly who
may need mostly orally applied co-medication. It should be
kept in mind that due to buprenorphine’s high affinity for
the µ-opioid receptor and its long duration of action, newly
applied analgesics may not work until the clinically relevant
doses of buprenorphine level off after the final removal of
buprenorphine patches. During continuous therapy with
buprenorphine patches, this long duration of action of
buprenorphine is not a problem as the newly applied
buprenorphine patches need 12–24 hours until clinically
relevant plasma levels are reached.
Analgesic gaps are therefore unlikely as long as proposed
dosing schemes are followed, and transdermal bupren-Therapeutics and Clinical Risk Management 2006:2(1) 123
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orphine provides an effective and sustained dose-dependent
analgesia irrespective of patient age or pain syndrome. A
number of studies have been conducted to assess the
analgesic efficiency and tolerability of buprenorphine TDS
in long-term management of cancer and non-cancer pain.
In the long-term study referred to above (Likar et al 2005),
90% of the 239 patients (age range 27–86 years; mean 68
years) reported at least satisfactory pain relief. Forty-three
percent of patients rated their pain relief as good and
complete. In a post-marketing surveillance study over a total
period of 9 months in 13 179 patients with cancer and non-
cancer pain (age range 13–101 years; mean 68 years), 81%
reported pain relief to be “good” or “very good” at the end
of the study, whereas only 6% of the study population
considered that their previous analgesic treatment fell into
these categories (Griessinger et al 2005). The demographics
of this study emphasize the efficacy of buprenorphine TDS
in a wide range of pain conditions. The patient population
in this study included 3690 (28%) with cancer pain, the most
common specific diagnosis being lower respiratory tract
cancer, urogenital cancer, and breast cancer. Metastases were
present in 15% of cancer patients. Among the 9489 patients
suffering from non-cancer pain, musculoskeletal pain was
the most frequently reported condition (77%), pre-
dominantly back pain and joint/rheumatic pain. Neurogenic
pain (23%) was mainly a result of neuralgias, neuropathies,
or phantom pain.
In the long-term study (Likar et al 2005), patients were
allowed to control pain by sublingual buprenorphine tablets
as needed. The proportion of patients needing 1 mg
buprenorphine daily (ie, one tablet in addition to the patch)
remained remarkably stable throughout the first 6 months
of the study indicating dose stability of buprenorphine under
long-term conditions. In another postmarketing surveillance
study on transdermal fentanyl in cancer patients over a
period of 4 months, it was found that most patients required
a dose increase during the observation period, the median
dose increasing from 1.2 mg/day to 2.4 mg/day (Radbruch
et al 2001).
The transdermal application reduces the occurrence of
adverse events since the plasma buprenorphine concentra-
tion remains stable. In the post-marketing surveillance study
of buprenorphine use, out of a total of 13 179 patients, 520
(4%) experienced nausea and 210 (1.6%) experienced
vomiting. Constipation was reported in 1.0% of the subjects.
A subgroup analysis of elderly patients (> 60 years) found
little change in this value (1.1%) (Griessinger et al 2005).
This compares favourably with a survey of the use of
transdermal fentanyl in 1005 patients (mostly with cancer
pain) where the incidence of constipation was 4% (Radbruch
et al 2001).
Buprenorphine has a lower risk of CNS-related adverse
events than other opioids. A comparison of the two surveys
mentioned above found the incidence of CNS effects in
patients receiving long-term transdermal buprenorphine was
lower than in patients receiving long-term transdermal
fentanyl. Somnolence, hallucinations, vertigo, and
convulsions were experienced by 0.8%, 0.009%, 0.002%,
and 0.001% of the subjects in the buprenorphine survey but
by 4.0%, 0.2%, 1.0%, and 0.1%, respectively, in the fentanyl
survey. One and half percent of the buprenorphine patients
reported dizziness (data unavailable in fentanyl patients)
which may in some instances respond to a dopamine
antagonist.
Local skin reactions at patch site may occur and clinical
trials have shown that such occurrences are irrespective of
whether buprenorphine or placebo were involved. These
reactions are most likely due to patch material or adhesive.
In a study comparing three different dose strengths of
buprenorphine TDS with placebo, patch application was well
tolerated, only 10% to 20% of all subjects in all four groups
reported local adverse events, but these were not statistically
significant. Local skin reactions, predominately consisted
of mild to moderate erythema or pruritus lasting less than
24 hours (Böhme and Likar 2003). In a long-term study of
buprenorphine use, local skin reactions at the patch site
occurred in 20.5% of patients. Most frequently these were
erythema (12.1%), pruritus (10.5%), and exanthema (8.8%)
(Likar et al 2005). In the post-marketing surveillance study,
the overall occurrence of local adverse effects was much
lower. Contact dermatitis was seen in only 0.8% of the
subjects and pruritus in only 0.7% (Griessinger et al 2005).
Adherence to therapy or compliance is a major
prerequisite for therapeutic success in the treatment of
chronic pain. Convenient drug handling and limited side
effects are key points in ensuring patient compliance. The
study of the extended wearing time has resulted in the
registration of the patch for a duration of application of up
to 4 days (96 hours) allowing regular patch changes on 2
fixed days a week (Likar 2005), which is easier to remember
for elderly patients and carers. In the post-marketing
surveillance study, patient compliance at the end of the
observation period was 91%. The fact that 70% of the
patients continued with buprenorphine TDS after completion
of the study indicates that it is not only effective, but also
easy and convenient to use (Griessinger et al 2005).Therapeutics and Clinical Risk Management 2006:2(1) 124
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Conclusions
Buprenorphine has been widely used and studied for over
20 years and shown to be an effective opioid analgesic. The
µ-agonistic profile of buprenorphine, combined with high
analgesic potency and efficacy, good safety profile, ease of
opioid switch, and reversibility by µ-antagonists makes this
drug a valuable option for long-term treatment in a wide
range of chronic pain indications. By using the transdermal
formulation of buprenorphine, the rate of drug delivery can
be controlled and stable plasma concentrations achieved.
The transdermal administration route is an advantage for
long-term use in ease of handling, increased patient
compliance, and cost-effectiveness of treatment.
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